This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Nektar Therapeutics’s 8K filing here.
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.
Featured Stories
- Five stocks we like better than Nektar Therapeutics
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
- What is the Shanghai Stock Exchange Composite Index?
- MarketBeat Week in Review – 11/4 – 11/8
- What is a Bond Market Holiday? How to Invest and Trade
- Trump’s Return: Which Sectors Will Benefit Most?
